(Q40518542)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

review article

1 reference

title

Therapy for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

5

Hafler DA

2 references

21 September 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

author name string

Weiner HL

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

Hohol MJ

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

Khoury SJ

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

Dawson DM

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

publication date

1 February 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

page(s)

173-196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion

24 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Antigen‐driven tissue‐specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein‐induced experimental autoimmune encephalomyelitis in the SJL mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Optic neuritis treatment trial. One-year follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Myelin basic protein administration in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Manipulating the Immune System with Immune Globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Failure of basic protein therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

T cell vaccination in multiple sclerosis: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

MS: a CNS and systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Megadose corticosteroids in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Interferon beta augments suppressor cell function in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Randomised double blind controlled trial of cyclosporin in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Clinical viral infections and multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

1 reference

7 January 2021

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

An open trial of OKT3 in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2818%2930066-5

7 January 2021

10.1016/S0733-8619(18)30066-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7739502%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference